Home > Pulmonology > ERS 2018 > Current look on asthma > From Clinical, Anatomical, Pathophysiological, and Inflammatory Subsets to Molecular Pathways

From Clinical, Anatomical, Pathophysiological, and Inflammatory Subsets to Molecular Pathways

Conference
ERS 2018

From clinical, anatomical, pathophysiological, and inflammatory subsets to molecular pathways

Based on growing insights into the underlying mechanisms of asthma during the past 3 decades, our look on asthma has evolved from the archetypic ‘’generalistic’’ syndrome to distinct disease subsets [1-3]. As in most diseases, the clinical expression (phenotype) of the different asthma subsets results from the combined effect of an individual’s genome and exposome (environmental exposures, microbiome, stress, life style, antibiotics) and their interactions [4]. Consequently, asthma should in fact be evaluated and subsequently treated at several levels: i.e. clinical (age of onset, comorbidities, systemic presentations); anatomical (e.g. bronchiectasis, small airways disease/airway remodelling); physiological (e.g. airway narrowing, (non-)reversibility, airway hyperresponsiveness, airway trapping, ventilation, hypoxemia); and immuno-inflammatory (cells, cytokines, ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on